Novo Nordisk to boost oral GLP-1 manufacturing via $92.5M buy for Alkermes’ Ireland facility

No­vo Nordisk will buy Alk­er­mes’ tablet­ing fa­cil­i­ty in Athlone, Ire­land, for $92.5 mil­lion in cash to man­u­fac­ture one of its block­buster GLP-1 drugs — Ry­bel­sus — as well as fu­ture prod­ucts, ac­cord­ing to a No­vo spokesper­son.

Alk­er­mes sell­ing its fa­cil­i­ty is al­so a part of its plans to be­come a pure-play neu­ro­science com­pa­ny. Last month, Alk­er­mes’ on­col­o­gy unit spun out to be­come Mur­al On­col­o­gy, an in­de­pen­dent, pub­licly-list­ed $MU­RA com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.